Medergie is a part of a wider group of companies that is growing through the development and acquisition of novel technologies that translate into exciting new medical products that have innovative and compelling value propositions or breakthrough improvements in clinical outcomes.
Medergie products target large and/or rapidly growing markets where there is clear evidence or compelling reasons customer adoption, efficient sales cycles and repeat sales.
Medergie technologies have proprietary advantages through defendable intellectual property and/or market positions upon which significant equity valuations can be built.
Our group's business models are focused on recurring and compounding revenues, attractive margins and short cash cycles. Our operating models ensure limited asset intensity, capital efficiency and optimal leveraging where increasing sales significantly impact on EBITDA.
The company is led by a team of entrepreneurially-driven executives with proven track records, uncompromising integrity and exceptional ambition and energy.
Our objective is to collaborate with inventors around the world to accelerate the development of disruptive Neuromodulation technologies under the following structures:
- Joint Venture
- Licensing / Royalty / Franchise Agreements
- Scientific collaboration agreements
Contact us:
Email: info@medergie.com
